Lanean...
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms. Phase III clinical studies have...
Gorde:
| Argitaratua izan da: | J Hematol Oncol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4222119/ https://ncbi.nlm.nih.gov/pubmed/24283870 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-79 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|